Why IMU is a multi multi bagger, page-23199

Drawing from previous timelines presented by IMU and updates in the Quarterly Report, the forthcoming Azer cel update could serve as a significant catalyst. Upon examining the product in a bit more detail, it is clear why Leslie consistently demonstrates excitement in leading with discussions about Azer cel.

Precision’s phase 1a trial involved dose escalation to determine the optimal dosage. I confirmed with Imugene that patients are being treated with the final dose of 500 x 10^6, identified as the Optimal Biological Dose (OBD), after producing impressive results as detailed in earlier Precision presentations.



Of the six subjects receiving the DL4b dosage (5/5 were evaluable), all achieved CRs (100%). The sixth “subject was deemed non-evaluable for efficacy at Day 28 due to a death occurring on Day 23, yet complete resolution was observed on CT at Day 21”



I'm hoping for even more favorable outcomes in the new Phase 1b cohort whilst using the most effective dose, I believe Imugene is also employing drug lot version 1.2, although I couldn’t find the specific details on this.